// App-Quantinova.ai

P1-19-16 : Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: An updated analysis

Researchers

Presenter

  • Richard S Finn

Principal Investigators

  • Hope S Rugo

  • Karen Gelmon

  • Massimo Cristofanilli

  • Marco Colleoni

  • Sherene Loi

  • Patrick Schnell

  • Dongrui R Lu

  • Kathy P Theall

  • Ave Mori

  • Eric Gauthier

  • Eustratios Bananis

  • Nicholas C Turner

  • Vronique Diras

Medical Centers

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Istituto Europeo di Oncologia, Milano, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Pfizer Inc, New York, NY

  • Pfizer Inc, San Diego, CA

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc, Milan, Italy

  • Amgen Inc, South San Francisco, CA

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Centre Eugene-Marquis, Rennes, France

Locations

  • United States

  • Canada

  • Italy

  • Australia

  • United Kingdom

  • France

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Fulvestrant

  • Palbociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • NCT00721409

  • NCT01740427

  • NCT01942135

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved